Chiral gold(I) vs chiral silver complexes as catalysts for the enantioselective synthesis of the second generation GSK-hepatitis C virus inhibitor
2011

Chiral Gold and Silver Complexes as Catalysts for Hepatitis C Virus Inhibitor Synthesis

publication Evidence: moderate

Author Information

Author(s): Martín-Rodríguez María, Nájera Carmen, Sansano José M, de Cózar Abel, Cossío Fernando P

Primary Institution: Universidad de Alicante

Hypothesis

The study investigates the effectiveness of chiral gold(I) and silver(I) complexes as catalysts in the enantioselective synthesis of a hepatitis C virus inhibitor.

Conclusion

The chiral phosphoramidite/silver(I) complexes showed higher enantioselectivity compared to gold(I) complexes in the synthesis of the hepatitis C virus inhibitor.

Supporting Evidence

  • The study achieved a 99% enantiomeric excess in the synthesis of the hepatitis C virus inhibitor.
  • Chiral phosphoramidite/silver(I) complexes were found to be more effective than gold(I) complexes in this reaction.
  • DFT calculations were used to explain the origin of enantioselectivity in the reactions.

Takeaway

Scientists are trying to make better medicines for hepatitis C by using special metal catalysts to help create the drugs in a way that makes them work better.

Methodology

The study involved the enantioselective 1,3-dipolar cycloaddition reaction using chiral phosphoramidites and silver or gold complexes as catalysts.

Limitations

The study primarily focused on specific chiral ligands and may not encompass all possible catalysts or conditions.

Digital Object Identifier (DOI)

10.3762/bjoc.7.111

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication